Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The 2025 National Basic Medical Insurance Drug List has been published, adding 114 new drugs, with a negotiation/competitive bidding success rate of 88%, higher than the 76% in 2024. The total number of drugs in the insurance list has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [12]. - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of 14.65% against the CSI 300's 16.43%, resulting in a 1.77 percentage point lag [21]. - The current valuation of the pharmaceutical sector is 33.0 times PE based on 2026 earnings forecasts, representing a 41% premium over the overall A-share market (excluding financials) [21]. Summary by Sections Recent Performance - The pharmaceutical and biotechnology sector has seen a decline of 1.04% in the past week, ranking 17th among 31 primary sub-industries. The sub-sectors of chemical pharmaceuticals, biological products, medical devices, pharmaceutical commerce, traditional Chinese medicine, and medical services have experienced weekly changes of -0.75%, -1.85%, -1.79%, -4.26%, -2.03%, and +1.67%, respectively [11][22]. Market Dynamics - The pharmaceutical sector's performance from the beginning of 2025 to December 12 shows a return of 14.65%, while the CSI 300 index returned 16.43%, indicating a relative underperformance of 1.77 percentage points [21]. Valuation Analysis - The current valuation of the pharmaceutical sector is 29.0 times PE based on trailing twelve months (TTM) earnings, which is below the historical average of 35.0 times PE from January 4, 2010, to December 12, 2025. The sector's premium over the overall A-share market (excluding financials) is 16.3% [21]. Industry Developments - The first commercial health insurance drug list has been established, including 19 drugs that enjoy various policy benefits. This list is effective from January 1, 2026, to December 31, 2027, and includes five CAR-T products [12].

www.hczq.com 证券研究报告 | 医药生物 | 2025年12月13日 华创医药投资观点&研究专题周周谈 · 第154期 2025Q3实体药店市场分析 本周专题联系人：高初蕾 华创医药团队： | 首席分析师 | 郑辰 | | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | --- | --- | --- | --- | --- | | 联席首席分析师 | | 刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长 | | 李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 | | 高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 分析师 | 王宏雨 | | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 分析师 | 朱珂琛 | | 执业编号：S0360524070007 | 邮箱：zhukechen@h ...

证券之星消息，12月12日医疗服务板块较上一交易日上涨1.17%，益诺思领涨。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出2.4亿元，游资资金净流入1.35亿元，散户资金净 流入1.05亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | | 5.03 Z | 30.20% | -2.10 Z | -12.62% | -2.93 Z | -17.58% | | 300015 | 爰尔眼科 | | 5317.94万 | 8.82% | -6481.96万 | -10.74% | 1164.02万 | 1.93% | | 300759 | 康龙化成 | | 3575.66万 | 3.45% | -2598 ...

Investment Rating - The report maintains a "Buy" rating for certain stocks in the CXO sector, indicating a positive outlook for the industry [58]. Core Insights - The global market is showing signs of recovery, with domestic financing on the rise, particularly in the healthcare sector. In Q3 2025, global financing reached $20.6 billion, marking a 39% increase and the highest in nearly four years. Domestic financing also surged to 18.2 billion yuan, up 97% [2][21]. - The IPO landscape is experiencing a divergence, with overseas markets facing challenges while domestic IPOs are rebounding. The domestic biotech IPOs have seen significant growth, with a 665% year-on-year increase in fundraising [30][34]. - The research and development sector is under pressure globally, but domestic R&D is showing rapid improvement, with new clinical trials reaching historical highs. In the first eleven months of 2025, the number of new clinical trials in China increased by 20% [41][52]. Summary by Sections Financing Sector - Global financing in the healthcare sector is recovering, with Q3 2025 showing a significant rebound. The total financing for the first ten months of 2025 has already surpassed the entire year of 2024 [14][21]. - Domestic financing trends mirror global patterns, with a notable increase in Q3 2025, indicating a clear upward trajectory [21][22]. IPO Trends - The overseas IPO market is stabilizing after a downturn, while domestic IPOs are experiencing a resurgence, particularly in the biotech sector, driven by a favorable secondary market [30][34]. - The first eleven months of 2025 saw a dramatic increase in fundraising from domestic biotech IPOs, highlighting a strong recovery [34][36]. R&D Developments - Globally, the number of new clinical trials is declining, but the domestic market is witnessing a significant turnaround, with new drug IND applications showing stability and growth [41][47]. - The number of new clinical trials in China has reached a historical high, with a notable increase in Phase II trials, indicating a robust pipeline for future drug development [52][53].

证券之星消息，12月5日医疗服务板块较上一交易日下跌0.03%，ST中珠领跌。当日上证指数报收于 3902.81，上涨0.7%。深证成指报收于13147.68，上涨1.08%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 10.77 | 10.01% | 51.19万 | 5.31亿 | | 920670 | 数字人 | 15.35 | 3.23% | 3.19万 | 4843.18万 | | 688710 | 益诺思 | 41.99 | 2.89% | 1.38万 | 5757.13万 | | 301096 | 百诚医药 | 54.49 | 2.48% | 2.61万 | 1.41亿 | | 301267 | 华屋眼科 | 18.90 | 2.27% | 6.22万 | 1.17亿 | | 002622 | 皓宸医疗 | 3.37 | 2.12% | 19.61万 | 6549.95万 | | 002173 | 创新医疗 | 22 ...

证券日报网讯12月2日，益诺思在互动平台回答投资者提问时表示，为遵循信息披露的公平原则，公司 会在定期报告中披露对应时点的股东信息。 ...

Core Viewpoint - The medical services sector experienced a decline of 2.05% on December 2, with Yinosh leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with ST Zhongzhu closing at 2.95, up 3.51%, and Yinosh closing at 41.58, down 7.27% [1][2]. - The total net outflow of main funds in the medical services sector was 9.53 billion yuan, while retail investors saw a net inflow of 6.87 billion yuan [2][3]. Group 2: Individual Stock Analysis - ST Zhongzhu had a trading volume of 1.27 million hands and a transaction amount of 372 million yuan, while Yinosh had a trading volume of 19,500 hands and a transaction amount of 82.48 million yuan [1][2]. - The stock performance varied, with some stocks like Innovation Medical and Dean Diagnostics showing slight declines, while others like ST Zhongzhu showed gains [1][2]. Group 3: Fund Flow Analysis - Main funds showed a net inflow in stocks like Innovation Medical (63.01 million yuan) and Dean Diagnostics (20.61 million yuan), while there were net outflows in several other stocks [3]. - Retail investors contributed to the net inflow in stocks like Innovation Medical and Dean Diagnostics, despite overall sector outflows [3].

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index down 0.42% to 3897 points, the Shenzhen Component Index down 0.68%, and the ChiNext Index down 0.69% [1][2] - The total market turnover was 1.61 trillion yuan, a decrease of 282.2 billion yuan compared to the previous trading day, with over 3700 stocks declining [1] Index Performance - Shanghai Composite Index: 3897.71, down 16.29 points (-0.42%) [2] - Shenzhen Component Index: 13056.70, down 90.02 points (-0.68%) [2] - ChiNext Index: 1398.13, down 10.66 points (-0.76%) [2] - Other indices such as the STAR Market 50 and the CSI 500 also showed declines [2] Sector Performance - The top-performing sectors included forestry (+3.53%), road transportation (+1.32%), and packaging (+0.93%) [2] - Notable stocks that surged included Pingtan Development, Ruineng Technology, and Fujian Expressway, all hitting the daily limit [2] - Conversely, the CRO sector saw a decline, with Yinuosi dropping over 7%, and lithium mining concepts also fell, led by Xizang Chengtou [3]

Group 1 - The major shareholder, Zhangjiang Biopharmaceutical Base Development Co., Ltd., holds 11,020,753 shares, accounting for 7.82% of the total share capital of the company [1] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [1] - The reduction will be executed through centralized bidding, and the selling price will be determined by market conditions [1][2] Group 2 - The major shareholder has made commitments regarding the holding period and reduction methods, including a lock-up period of 12 months for shares held before the IPO and 36 months for shares obtained through capital increase [2][3] - The reduction plan is consistent with previous commitments made by the major shareholder [4] - The company confirms that the reduction will not lead to a change in control and will not significantly impact the company's ongoing operations [5]

博菲电气实控人的一致行动人拟减持不超过2.9497%股份；数据港股东宁波锐鑫拟减持不超3.00%股份；长川科技（维权）实 控人之一致行动人拟减持不超过1.8866%股份；ST未名（维权）股东高宝林及其一致行动人王明贤拟减持不超过3%股份；芳 源股份股东平方亿利拟减持不超1%股份；益诺思股东张江生药基地拟减持不超1.00%股份；三江购物股东阿里泽泰减持547.68 万股公司股份；天府文旅股东莱茵达集团及一致行动人高靖娜累计减持3.95%股份；远大智能（维权）公司股票交易将被实施 其他风险警示 股票停牌；*ST元成（维权）股票将于12月5日终止上市暨摘牌 | | | 12月1日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 | 主要内容 | | | 博菲电气 | 实控人的一致行动人拟减持不超过2.9497%股份 | | | 数据港 | 宁波锐鑫拟减持不超3.00%股份 | | | 长川科技 | 实控人之一致行动人拟减持不超过1.8866%股份 | | | ST未名 | 高宝林及其一致行动人王明贤拟减持不超过3%股份 | | | 研學股份 | 王平拟减持1.49%股份 | | | S ...